EU legislation
This article was originally published in The Tan Sheet
Executive Summary
New EU medicines legislation comes into effect Oct. 30, requiring all drugs authorized after that date to carry the name of the medicine in Braille and provide additional aid to patients suffering from sight loss, such as leaflets in large print and audio versions of Patient Information Leaflets made available in CD and tape format. The legislation also deems it a criminal offense if companies fail to submit new information that may affect the risk/benefit ratio of a product. The EU directive on Herbal Medicines also comes into effect Oct. 30, requiring herbal manufacturers to register their products prior to sale, rather than selling them as unlicensed herbal remedies. The UK's Medicines & Healthcare products Regulatory Agency sought comments on the directive's implementation in June (1"The Tan Sheet" July 4, 2005, p. 14)...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.